Item 5.07 Submission of Matters to a Vote of Security Holders

On October 22, 2021, TCR2 Therapeutics Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders considered and voted on the two proposals set forth below, each of which is described in greater detail in the Company's Proxy Statement filed with the Securities and Exchange Commission on September 3, 2021. The final voting results are set forth below.

Proposal 1 - Election of Class III Director Nominees

The stockholders of the Company elected Garry E. Menzel, Ph.D., Ansbert Gadicke, M.D., and Neil Gibson, Ph.D., as a Class III directors, for a three-year term ending at the annual meeting of stockholders to be held in 2024 and until each director's successor has been duly elected and qualified or until his earlier resignation or removal. The results of the stockholders' vote with respect to the election of the Class III directors were as follows:





                              Votes             Votes          Broker
Name                           For            Withheld        Non-Votes
Garry E. Menzel, Ph.D.     23,062,461.41       3,651,095       3,803,285
Ansbert Gadicke, M.D.      23,230,375.41       3,483,181       3,803,285
Neil Gibson, Ph.D.         23,282,444.41       3,431,112       3,803,285

Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm

The stockholders of the Company ratified the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021. The results of the stockholders' vote with respect to such ratification were as follows:





    Votes        Votes               Broker
     For        Against   Abstain   Non-Votes
30,489,743.41   21,712     5,386        0

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses